Literature DB >> 15852220

The P2 receptors and congenital platelet function defects.

Marco Cattaneo1.   

Abstract

Platelets possess three P2 receptors: two (P2Y (1) and P2Y (12)) are receptors for adenosine diphosphate (ADP), and one (P2X1) is a receptor for adenosine triphosphate (ATP). The P2Y (1) receptor, which is coupled to Gq and phospholipase C-beta, is responsible for mobilization of ionized calcium from internal stores and mediates the ADP-induced platelet shape change and initial wave of rapidly reversible aggregation. The other ADP receptor, P2Y (12), is negatively coupled to adenylyl cyclase through Gi and mediates a progressive and sustained ADP-induced aggregation not preceded by shape change. In addition, this receptor plays an important role in the potentiation of platelet secretion induced by several platelet agonists. The combined action of P2Y (1) and P2Y (12) is necessary for the full platelet aggregation response to ADP. Four patients with severe deficiency of P2Y (12) have been described so far. Sequence analysis of the P2Y (12) locus of three of these patients revealed homozygous mutations that produced a frame shift mutation and premature truncation of the protein. The fourth patient had an allele with a frame shift mutation and a normal allele, which could be silenced by an additional, as yet unknown, mutation. More recently, we described a patient with a congenital bleeding disorder and a dysfunctional P2Y (12). The patient is a compound heterozygote, in whom one allele contained a G to A transition resulting in an Arg (256) to Gln codon substitution (R256Q) and the other allele contained a C to T transition resulting in an Arg (265) to Trp codon substitution (R265W). The two substitutions are located in TM6 and EL3 of the receptor. Stable Chinese hamster ovaries (CHO) cell lines were established expressing either wild-type P2Y (12) and P2Y (12)(R256Q) or P2Y (12)(R265W). Neither mutation blocked the ability of the P2Y (12) receptor to translocate to the CHO cell surface. ADP at all tested concentrations (0.1 to 10 muM) greatly inhibited the forskolin-induced increase of cyclic adenosine monophosphate (cAMP) in CHO cells transfected with wild-type P2Y (12), whereas CHO cells transfected with either mutant protein were only partially inhibited by ADP. Thus, the molecular basis for the patient's dysfunctional platelet phenotype is explained by missense mutations and the expression of a dysfunctional P2Y (12) receptor. The localization of both mutations in TM6 and EL3 identifies this region of P2Y (12) as a structurally and functionally critical region of the receptor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15852220     DOI: 10.1055/s-2005-869522

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  11 in total

Review 1.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

2.  Structure of the human P2Y12 receptor in complex with an antithrombotic drug.

Authors:  Kaihua Zhang; Jin Zhang; Zhan-Guo Gao; Dandan Zhang; Lan Zhu; Gye Won Han; Steven M Moss; Silvia Paoletta; Evgeny Kiselev; Weizhen Lu; Gustavo Fenalti; Wenru Zhang; Christa E Müller; Huaiyu Yang; Hualiang Jiang; Vadim Cherezov; Vsevolod Katritch; Kenneth A Jacobson; Raymond C Stevens; Beili Wu; Qiang Zhao
Journal:  Nature       Date:  2014-03-23       Impact factor: 49.962

3.  Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12.

Authors:  Philipp Schmidt; Lars Ritscher; Elizabeth N Dong; Thomas Hermsdorf; Maxi Cöster; Doreen Wittkopf; Jens Meiler; Torsten Schöneberg
Journal:  Mol Pharmacol       Date:  2012-10-23       Impact factor: 4.436

Review 4.  Inherited platelet disorders: thrombocytopenias and thrombocytopathies.

Authors:  Giovanna D'Andrea; Massimiliano Chetta; Maurizio Margaglione
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

Review 5.  Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists.

Authors:  Indera Anita Jagroop
Journal:  Purinergic Signal       Date:  2013-11-05       Impact factor: 3.765

6.  Activation of microglial P2Y12 receptor is required for outward potassium currents in response to neuronal injury.

Authors:  P Swiatkowski; M Murugan; U B Eyo; Y Wang; S Rangaraju; S B Oh; L-J Wu
Journal:  Neuroscience       Date:  2016-01-12       Impact factor: 3.590

Review 7.  Novel uses for anti-platelet agents as anti-inflammatory drugs.

Authors:  S C Pitchford
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

8.  Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.

Authors:  Nianjun Liu; Marguerite R Irvin; Degui Zhi; Amit Patki; T Mark Beasley; Deborah A Nickerson; Charles E Hill; Jinbo Chen; Stephen E Kimmel; Nita A Limdi
Journal:  Pharmacogenomics       Date:  2017-07-07       Impact factor: 2.533

9.  Inhibitory effects of total saponin from Korean Red Ginseng on [Ca(2+)]i mobilization through phosphorylation of cyclic adenosine monophosphate-dependent protein kinase catalytic subunit and inositol 1,4,5-trisphosphate receptor type I in human platelets.

Authors:  Jung-Hae Shin; Hyuk-Woo Kwon; Hyun-Jeong Cho; Man Hee Rhee; Hwa-Jin Park
Journal:  J Ginseng Res       Date:  2015-03-28       Impact factor: 6.060

Review 10.  What's new in using platelet research? To unravel thrombopathies and other human disorders.

Authors:  Kathleen Freson; Veerle Labarque; Chantal Thys; Christine Wittevrongel; Chris Van Geet
Journal:  Eur J Pediatr       Date:  2007-07-10       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.